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Summary 
Spi-B and PU.1  are hematopoietic-specific transcription factors that constitute a subfamily of 
the  Ets family of DNA-binding proteins.  Here we  show that  contrary to previous reports, 
PU.1  and Spi-B have very different expression patterns. PU.1 is expressed at high levels in B 
cells, mast cells,  megakaryocytes, macrophages, neutrophils, and immature erythroid cells and 
at lower levels in mature erythrocytes. PU.1  is completely absent from peripheral T  cells and 
most T  cell lines based on sensitive R.T-PCR assays. In contrast, Spi-B is expressed exclusively 
in lymphoid cells and can be detected in early fetal thymus and spleen. In situ hybridizations of 
adult murine tissues demonstrate Spi-B mRNA in the medulla of the thymus, the white pulp 
of the spleen, and the germinal centers of lymph nodes. Spi-B expression is very abundant in B 
cells and both Spi-B mR.NA and protein are detected in some T  cells. In situ hybridization and 
Northern blot analysis  suggest that Spi-B gene expression increases during B  cell maturation 
and decreases during T  cell maturation. Gel-retardation experiments show that Spi-B can bind 
to all putative PU.1 binding sites, but do not reveal any preferred Spi-B binding site.  Finally, 
both PU.1 and Spi-B function as transcriptional activators of the immunoglobulin light-chain 
enhancer  E~2.4 when  coexpressed  with  Pip  (PU.l-interaction  partner)  in  NIH-3T3  cells. 
Taken together, these data suggest that differences in patterns of expression between Spi-B and 
PU. 1 distinguish the function of each protein during development of the immune system. 
H 
ematopoiesis  generates  eight  distinct  lineages  from 
self-renewing  pluripotential  stern  cells,  which  then 
differentiate into mature blood cells. The molecular mech- 
anisms  underlying self-renewal and lineage commitment of 
stem cells have not been resolved. However, the process is 
regulated  in  part  by  hematopoietic-specific  transcription 
factors. For example, stem cell leukemia (SCL) 1 is required 
for yolk sac  hematopoiesis  (1,  2),  GATA-1  regulates red 
cell maturation (3, 4);  Ikaros is important for the develop- 
ment of lymphocytes, natural killer cells,  and neutrophils 
(5, 6); and Oct-2 is essential  for T  cell-independent B  cell 
activation and B  cell maturation into immunoglobulin se- 
creting cells (7, 8). The function of a transcription factor in 
hematopoiesis is somewhat correlated to its expression pat- 
tern.  PU.1  is expressed at high levels in B  cells,  granulo- 
cytes, monocytes, and immature erythroid cells (9,  10,  11, 
12).  We  have  previously determined  that  PU.1-/--defi- 
1Abbreviations used in this paper: CAT, chloramphenical acetyl  transferase; 
DN, double negative; DP, double positive; EMSA, electrophoretic  mo- 
bihty shift assays; Fc~/R, Fc fragments; IVT, in vitro-translated; RT, re- 
verse transcribed; SCL, stem cell leukemia; SP, single positive. 
cient embryos die between days 16 and 18 of gestation and 
mutant embryos do not produce T and B lymphocytes, gran- 
ulocytes, and monocytes (13).  In  addition,  some  day  16.5 
embryos are also anemic (13). 
Transcription factors of the Ets family are widely studied 
as key regulators of genes involved in the immune response 
and cellular prohferation. Spi-B and PU.1  are members of 
the Ets family, which now includes ~20 members. Spi-B 
was  cloned from a Burkitt lymphoma cDNA hbrary using 
the human PU.1 Ets DNA-binding domain as a probe (12), 
and  it shares  a  67%  amino  acid Ets-domain  identity and 
43%  overall amino  acid  sequence identity to  PU.1  (12). 
Like most of the Ets family members, Spi-B has the DNA- 
binding domain at its basic carboxy terminus and an acidic 
amino-terminal domain that corresponds to the transactiva- 
tional domain in PU.1.  PU.1  and Spi-B are the most dis- 
tantly related genes to  other Ets family members, as their 
Ets domains present only 40% identity to Ets-1  (12). Spi-B 
can bind specifically to the putative PU.1  binding site in 
the  SV40  promoter,  and  can also  transactivate  a reporter 
construct  containing  multiple  PU  boxes.  Ray  et  al.  re- 
ported that Spi-B has an identical pattern of expression to 
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T  cells (12). 
Here we report that significant amounts of Spi-B mRNA 
are detected in B  and T  cells, but not in monocytic cells. 
On the contrary, PU. 1 mP,.NA can not be detected by the 
most sensitive means, such as tLT-PCP,, in purified human 
peripheral T  cells or any T  cell lines examined. Spi-B is not 
present in  any  other non-lymphoid cells based on  in situ 
hybridization analyses. Spi-B is first expressed in  the fetal 
thymus  and  spleen,  and  Spi-B mP,  NA is localized to  the 
medulla of the thymus,  white pulp of the spleen, and the 
germinal centers of the lymph nodes of adult mice. Spi-B is 
able to bind to all predicted PU. 1-binding sites in vitro, in- 
cluding  myeloid  target  genes.  Both  Spi-B  and  PU.1  in 
Clone  13 B  cells bind to the functional PU.l-binding site 
in  the  IgK 3'  enhancer.  Both  Pu.1  and  Spi-B function  as 
transcriptional activators of the Igk 2-4 enhancer. We pos- 
tulate  that  Spi-B  plays an  important  role  in  lymphocytic 
development based on its pattern of expression. 
Materials  and Methods 
Northern Analysis and RT-PCR.  Total ILNAs were prepared 
from cells  or tissues  using Trizol (GIBCO BILL,  Gaithersburg, 
MD) according to the manufacturer's instructions. Poly-A  + R.NAs 
were then prepared from total cellular ILNAs using the Oligotex 
poly-A  §  miLNA purification protocol (QIAGEN,  Chatsworth, 
CA). Poly-A  + ILNA samples (2 ~g each) were separated by elec- 
trophoresis on  1.2%  agarose gels  containing formaldehyde and 
blotted onto Hybond-N+ membranes. Hybridizations were car- 
fled out at 42~  in 50% formamide, 50 mM hepes (pH 7.0), 5￿ 
Denhardt's solution, 3￿  SSC, 0.16 mg/ml salmon sperm DNA, 
0.1%  SDS,  and  5%  dextran  sulfate.  Membranes  were  washed 
twice in 2X SSC/0.1% SDS at room temperature for 10 rain, and 
twice in 0.1￿  SSC/0.1% SDS at 55~  for 30 rain. The human 
Spi-B probe  (3'-UTIL,  from  the  EcoiLV site in  Spi-B  to  the 
EcoiLI  site  in  pBluescript,  ,'~  bp  long)  and  murine  Spi-B 
probe (3'-UTIL, NdeI to BamHI, 600 bp long) were labeled by 
random hexapriming. 
For  ILT-PCIL  analysis,  total  ILNA  was  reverse  transcribed 
(ILT) in a 20-p2 volume with reagents from Perkin-Elmer (Nor- 
walk, CT): Moloney murine Leukemia virus reverse transcriptase 
(50 U), R.Nase inhibitor (20 U), dNTPs (1 mM final concentra- 
tion), Oligo d(t)l  6 (2.5  mM final concentration), MgC12 (5 mM 
final concentration), KC1 (50 mM final concentration), and Tris- 
HC1,  pH 8.3  (10  mM final concentration). Samples were incu- 
bated at 42~  for 15 min 99~  for 5 min, and 5~  for 5 rain. The 
salt concentration for PCIL was optimized using the Optiprime 
kit (Stratagene, La Jolla, CA) for each set of primers according to 
the manufacturer's instruction. The entire ILT reaction was sub- 
jected to 30 cycles of denaturation at 94~  for 1 rain, primer an- 
nealing at 65~  and primer extension at 72~  for 2 rain. 
Antibodies.  The coding sequence of human Spi-B cDNA was 
subcloned into the EcoR.I site of the bacterial expression vector 
pGEX-4T3 (Pharmacia, Piscataway, NJ). Spi-B-GST fusion pro- 
tein was induced at 1.25 mM IPTG and subsequently purified us- 
ing the Bulk GST Purification Module  (Pharmacia). Polyclonal 
anti-Spi-B antisera were obtained from rabbits immunized with 
the Spi-B-GST fusion protein (Pocono Rabbit Farm & Labora- 
tory, Canadensis, PA). Monodonal anti-PU. 1 antibody was pur- 
chased from Santa Cruz Biotechnology, Inc. 
In Vitro Translation and Western Blot Analysis.  IVT proteins were 
synthesized from human  Spi-B and murine PU.1  cDNA linked 
to the T7 promoter in pCDNA3 vectors using Promega TNT T7 
Coupled ILeticulocyte Lysate System. IVT proteins were quanti- 
tated by their [3SS]methionine  incorporation, to  determine that 
equal amounts of Spi-B and PU. 1 proteins were loaded for each 
assay. IVT proteins and total cell lysates obtained from 2  ￿  10  6 
cells each were subjected to  12%  SDS-polyacrylamide gel elec- 
trophoresis followed by electrotransfer onto  nitrocellulose. The 
membranes were probed with the polyclonal antiserum to Spi-B 
in 10 mM Tris, pH 7.5, 150 mM NaCI, and 5% nonfat milk. The 
immune complexes were revealed by the ECL Western blotting 
detection system  (Amersham Corp., Arlington Heights,  IL)  ac- 
cording to the manufacturer's instructions. 
Ceil Purification.  To purify splenic B cells, ammonium chloride- 
lysed spleen cells were subjected to anti-Thyl.2/complement de- 
pletion.  Splenic  T  cells  were  purified  from  red  cell-depleted 
spleens using a Mouse T  Cell Enrichment Column  (IL&D  Sys- 
tems, Minneapolis, MN)  and anti-JllD/complement lysis.  The 
purity of final cell populations was determined by flow cytometry 
using B220 (13 cell) and CD3  (T cell) surface antigens. Purified B 
cells were  determined to  be  98%  pure,  and  T  cells  were  85% 
pure. For T  cell sorting, adult BL/6  thymi were processed into 
single cell suspensions and resuspended at 5 3<  106 cells per ml in 
5%  complete media  (5%  fetal bovine  serum,  1￿  non-essential 
amino acids,  1￿  L-glutamine, 1 ￿  Pen-Strep, 50 I.tM [3-mercap- 
toethanol  in  DMEM).  Thymocytes were  incubated with  anti- 
CD4 and anti-CD8 antibodies (PharMingen, San Diego, CA) at 
1 p~g/106 cells for 30 min at 4~  The incubation was followed by 
two washes with complete media. Cells were resuspended at 4 ￿ 
106 cells/ml in complete media for sorting by flow cytometry. 
In Situ Hybridization.  Adult  murine  tissues  (thymus,  lymph 
nodes, heart, lung, spleen, and liver) were sectioned and mounted 
for in situ hybridization. Sense  and  anti-sense riboprobes were 
made  from  the  3'-UTIL  of murine  Spi-B  (NdeI  to  BamHI) 
linked to the T7 promoter in pBluescript. The protocol utilized 
was essentially as described by Eichele and coworkers (14).  Tis- 
sues were fixed in 4% paraformaldehyde/PBS and embedded in 
paraffin.  The sections were rehydrated and treated with 20 mg/ 
ml proteinase K,  and  0.1  M  triethanolamide-HCl, pH  8.  Pre- 
treated slides were hybridized overnight at 60~  The hybridiza- 
tion mix contained 50% formamide, 20 mM Tris-HCl, pH 8, 0.3 
mM NaCl, 5 mM EDTA,  10% dextran sulfate,  0.02%  BSA, 0.5 
mg/ml  tiLNA,  and  10  mM  DTT.  3SS-labeled  riboprobe  was 
mixed  with  the  hybridization mix  at  140,000  cpm/1  (90  ml/ 
slide).  A  1/100th  volume  of 25  mM  5'-alpha-thio-ATP was 
added to the probe mix, followed by 2 min of boiling. After hy- 
bridization, slides were washed with 50%  formamide, 2￿  SSC, 
and 20  mM  DTT  for 60  min  at  65~  (high stringency wash). 
Slide were then washed with STE (4￿  SSC, 20 mM Tris-HC1, pH 
7.6,  1 mM EDTA) for 10 min twice at 37~  followed by ILNase 
A  treatment (10 mg/ml in STE) for 30 min at 37~  This high 
stringency wash was repeated and then the slides were washed in 
2￿  SSC at 37~  for 10 min. 
Electrophoretic Mobility Shift Assays (EMSAs).  In  vitro-translated 
(IVT) proteins (1.3 ~1 to 1.5 I*1) or nuclear extracts (10 Ixg) were 
preincubated on ice with  1 Ixg of double-stranded poly(dI-dC) 
and 0.4 Izg of salmon sperm DNA in 5X  Ficoll binding buffer in 
a final volume of 19 p~l. For competition experiments, cold com- 
petitor oligonucleotide (200-300 ng per reaction) and pre-immune 
or antiserum were  also  added at  this step.  ILadiolabeled probes 
were diluted to 30,000 cpm/p.1 and 1 ~1 was added to the bind- 
ing reaction for a  10-rain incubation at room temperature. Oli- 
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tive PU.1 binding sites: 
c-fes  (15) 
GATCAAACCGCGGGAGGAGGAAGCGCGGAATCAGGA 
c-fes mutant  (15) 
GATCAAACCGCGGGAGCACCGGGCGCGGAATCAGGA 
SV40  (12) 
GATCTCGGGCTCGAGTCTGAAAGAGGAACTTGGTTA 
SV40 mutant  (12) 
GATCTCGGGCTCGAGTCTTGAAAGACCAACTTGGTT 
Ig~-3' enhancer  (16) 
GATCCCTTTGAGGAACTGAAAACAGAACCTAGATC 
IgJ chain  (17) 
CTAGATTTTAAGAAAGCAGAAGCAGCAT 
M-CSF receptor (18) 
TCGACCTAGCTAAAAGGGGAAGAAGAGGATCAGC 
Fc"/receptor  (19) 
CTAGGCAATTTCCCTTCCTCTTTTCTAA 
]3-globin  (11) 
GATCACCTTCCTATCAGAAAAAAAGGGGAAGCGATTAT 
Transient Transfection and CA T Assays.  The CAT reporter con- 
struct  (B4TKCAT)  containing multiple  copies  of the PU.1/Pip 
binding site  of the  lambda  chain  enhancer Ek2_4, has  been  de- 
scribed  previously (20). To create  Pip/CMV the Pip cDNA was 
subcloned as a HindllI-XbaI fragment into the HindlII and Xbal 
sites in the  polylinker of pRc/CMV  (Invitrogen), which places 
the cDNA insert  under the control of the CMV promoter (21). 
NIH-3T3 cells were transfected  using Lipofectin (GIBCO BRL) 
and a total of 25 btg of DNA. Transfection involved 5 ~g of re- 
porter construct and 10 Ixg of the expression  constructs,  with the 
balance  made  up  with  empty expression  vector.  After 48  h  at 
37~  cell lysates were prepared and CAT assays performed using 
30 txl oflysate as described  previously (20). TLC plates were ana- 
lyzed  on  a  Molecular  Dynamics  Phosphorlmager;  the  results 
shown  here  represent  an  average  of at  least four independent 
transfections. 
Results 
Spi-B mRNAs Are Present Exclusively in Murine  Thymus, 
Spleen, and Lymph Nodes.  To  determine  the  tissue-speci- 
ficity  of Spi-B  mRNA  expression,  tissues  from  day  18.5 
mouse embryos and adult mice were analyzed on poly-A  + 
Northern  blots.  To  distinguish  the  expression  of Spi-B 
mRNA  compared to  PU.1  mRNA,  a  3'  untranslated  re- 
gion  (3'  UTR)  probe  for  the  mouse  Spi-B  cDNA  was 
used. Spi-B mRNA  has been previously detected in B  cells 
(12),  so  splenocytes  were  used  as  a  positive  control.  As 
shown in Fig.  1 A, high levels of Spi-B mRNA  were de- 
tected  in  adult  splenocytes  (see  lane  1).  The  predominant 
mRNA  species was 3.0 kb, in contrast to the 1.4-kb species 
found in human cells  (see  Fig. 6).  However,  a faint  1.5-kb 
species was  detected.  Surprisingly,  Spi-B  mRNA  was  de- 
tected at low levels in adult  thymocytes as well  (Fig.  1 A, 
lane 2). In contrast, Spi-B mRNAs were completely absent 
in all  fetal tissues  examined including heart,  kidney,  brain, 
and liver  (Fig.  1 A, lanes  3-6).  Adult murine  tissues were 
also examined for Spi-B expression,  including heart,  liver, 
lungs, lymph nodes, small intestine,  spleen,  and testes.  Be- 
Figure  1.  The  tissue distribution of Spi-B expression. (A)  The  top 
panel shows a Northern blot analysis of mRNA samples isolated from fe- 
tal murine tissues, adult splenocytes, and adult thymocytes  hybridized to a 
radiolabeled Spi-B 3' UTR probe (16-h exposure). The Spi-B probe hy- 
bridized primarily to a 3.0-kb species and a smaller 1.5-kb species present 
in purified splenocytes  and thymocytes.  The bottom panel shows  hybridiza- 
tion to the 1.4-kb glyceraldehyde  3-phosphate dehydrogenase (GAPDH) 
probe used as a control for the amount of  RNA in each lane. (B) The top 
panel shows a Northern blot analysis of RNA samples obtained from the 
indicated adult murine tissues (20-h exposure). A 3.0-kb transcript was 
detected in the spleen and lymph nodes; however, no 1.5-kb species was 
apparent in this experiment. GAPDH hybridization  is shown in the bot- 
tom panel A larger GAPDH transcript was observed in the testes sample. 
sides the spleen,  Spi-B mRNAs were also detected in axil- 
lary and mesenteric lymph nodes (Fig.  1 B, lanes  4 and  6). 
No other organs from adult mice exhibited significant Spi-B 
expression. 
To further localize Spi-B mRNA  expression, in situ hy- 
bridization was performed on adult mouse tissues.  In adult 
tissues,  Spi-B mRNA  was observed exclusively in the thy- 
mus, spleen,  and lymph nodes (Figs.  2  and 3).  Only back- 
ground  signals  were  detected  in  heart,  intestines,  kidney, 
stomach, lung,  and liver  (data not shown).  To assess posi- 
tive in situ hybridization, sense and antisense 3' UTR  Spi-B 
probes  were  incubated  with  tissue  sections.  As  shown  in 
Fig. 2, a,  d, and g, the sense probe gave weak hybridization 
signals as compared to the antisense probe (b, e, and h). He- 
matoxylin- and eosin-stained sections of thymus, spleen, and 
lymph nodes are shown for comparison (Fig.  2,  c, f,  and 0. 
In the thymus, Spi-B gene expression was restricted to the 
medulla  region  (Fig.  2,  b).  As T  cells  mature,  thymocytes 
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diolabeled sense 3' UTR Spi-B riboprobe (a, d, and g) and an antisense Spi-B riboprobe (b, e, and h). Specific hybridization was detected m the thymus 
medulla (b), white pulp of the spleen (e), and follicles and germinal centers of the lymph nodes (h). c.jl and i display hematoxylin- and eosin-stamed see 
tions of adjacent regions of the thymus, spleen, and lymph node for comparison. Magnification, 5￿ 
migrate from the  darkly staining  thymic  cortex to the  pale 
staining medulla where single positive T  cells undergo  neg- 
ative  selection.  In  the  spleen,  Spi-B  mP,,NA  was  abun- 
dantly  expressed  throughout  the  white  pulp,  except  the 
center portion which consists of arterioles and periarteriolar 
lymphocyte sheaths  (PALS)  (Fig.  2,  e).  The  PALS contains 
a  network  of antigen-presenting  cells,  such  as interdigitat- 
ing  dendritic  cells,  and  plasma  B  cells.  B  cells  congregate 
peripherally  to  the  PALS  in  primary follicles  and  germinal 
centers.  The outer most layer of the white pulp is the mar- 
ginal  zone,  which  contains  T  and  B  lymphocytes.  Spi-B 
mP,  NA is present in cells surrounding  the arterioles and the 
PALS in the white pulp of the spleen, where T  and B  lym- 
phocytes  reside.  In  lymph  nodes,  Spi-B  is  present  in  the 
primary follicles  (Fig.  2,  h  and  0.  Fig.  3,  shows  in situ  hy- 
bridization  analyses  with  the  thymus  (b),  spleen  (e),  and 
lymph  nodes  (h)  at  a  higher  magnification.  Spi-B  mtLNA 
was present in the periphery of the thymic medulla and the 
germinal  centers  of the  spleen  (b and  e).  Fig.  3  i,  shows  a 
resting  lymph  node  stained  with  hematoxylin  and  eosin; 
the primary follicles  reside  at the  edge.  Resting B  cells ac- 
cumulate in the follicles  which clearly express Spi-B (Fig.  3  h). 
Spi-B Expression  Is Restricted to the Thymu.s  and Sph'cn dur- 
i~Lg Munne Emb~Toge,esis.  To determine  the  temporal  and 
spatial  patterns  of expression  during  nlammalian  develop- 
ment, in situ hybridization  experiments were performed on 
tissue  sections  obtained  from  mouse  embryos  at  various 
gestational  stages.  Sense  and  antisense  3'  UTR  Spi-t3 
probes  were  hybridized  to  sections  of day  7.5,  8.5,  11}.5, 
14.5,  16.5,  and  19.5  mouse  embryos.  The  results  are sum- 
marized  in  Fig.  4  and  show  that  Spi-B  lnRNAs  were  de- 
tected exclusively in fetal thymus and spleen.  Spi-B expres- 
sion was first observed in the day 14.5  thymus (Fig. 4, ,/and 
c). All tissues in day 7.5,  8.5,  and  10.5  embry,  os failed to re- 
act  with  the  antisense  Spi-B  probe  and  gave  background 
signals similar to that observed with the control sense probe 
shown in Fig.  4  b.  Furthermore,  all other tissues in  the day 
14.5  embryo were  negative  for Spi-B  mR.NA  production 
(see  Fig.  4  a).  It is  interesting  to  note  that neither  the  day 
i4.5  or  day  16.5  spleen  exhibited  Spi-B  gene  expression. 
However,  when  sections  of day  19.5  embryos  were  hy- 
bridized  to  the  Spi-B  probe,  the  spleen  displayed  strong 
signal intensity  (Fig.  4  e). The control sense probe gave the 
expected  background  level  of hybridization  (Fig.  4  d).  In 
206  Ets Protein Spi-B Is Expressed Exclusively in B Cells and T Cells Figure 3.  The spatial pattern of expression  of Spi-B in adult thymus, spleen, and lymph nodes.  In situ hybridization was performed using radiolabeled 
sense Spi-B riboprobe (a, d, andg) and antisense Spi-B riboprobe (b, e, and h). c,f  and i depict hematoxylin- and eosin-stained adjacent sections of the 
thymus, spleen,  and lymph node, respectively.  Magnification, 10X. 
Figure 4.  The temporal and spacial patterns of Spi-B expression  during murine embryonic development. In situ hybridization assays were performed 
using the 3' UTR sense and antisense Spi-B riboprobes on day 14.5 and 19.5 mouse embryo tissue sections; a shows hybridization to the antisense probe. 
Magnification, 12.5￿  Sense and antisense Spi-B riboprobes were hybridized to day 14.5 embryonic tissues (b and c, respectively).  Magnification, 25X. 
d and e show hybridization to day 19.5 mouse embryo tissue sections with sense and antisense Spi-B riboprobes, respectively.  Magnification, 25X. Only 
the thymus and spleen exhibited Spi-B mRNA expression  during development. the  day  19.5  embryo,  Spi-B  hybridization  was  detected 
only in  the  thymus  and  spleen.  We  conclude  that  Spi-B 
gene  expression is  highly tissue  restricted  and can only be 
detected in the  developing lymphoid organs of the mouse 
embryo. 
Spi-B Expression Is Developmentally Regulated during T Cell 
and B Cell Development,  To further explore Spi-B expres- 
sion  during  B  cell  maturation,  immortalized  B  cell  lines 
representing  different  developmental  stages  were  studied. 
Low  level  Spi-B  expression  was  detected  in  pro-B  cells 
(NFS  70/c10 ceils;  Fig.  5  A, lane  1),  higher levels in one 
pre-B  cell  line  (38  B9  cells,  lane  2),  and  dramatically  in- 
creased levels  in mature B  cells such  as A20.1  and WEHI 
(lanes 4 and 5). Purified splenic B cells  exhibited high levels 
of Spi-B  as  well  (lane  8).  Low  levels  of Spi-B  mRNAs 
were  detected  in  the  immature  T  cell  line  EL-4  (lane  7) 
and  column  enriched,  anti-J11D/complement  depleted 
splenic T  cells.  To determine ifSpi-B transcription changes 
during  T  cell  maturation,  T  cells  were  sorted  into  the 
CD4- CD8-  (double negative:DN), CD4 § CD8 + (double 
positive:DP), and CD4 + or CD8 + single positive (SP) pop- 
ulations. Interestingly, Spi-B mRNA was most abundant in 
the CD4-  CD8-  "double negative" population (Fig. 5  C). 
Furthermore,  Rag2  -/-  thymi  express  higher  levels  than 
those  obtained  from C57BL/6  mice  (lanes  5  and  6).  Rag 
2 -/- thymi have previously been shown to contain no DP 
or SP T  ceils  and to contain essentially 98% DN cells  (22). 
These  results  are  consistent  with  Spi-B  expression  being 
highest  in  DN  T  cell  precursors.  Furthermore,  Spi-B  ex- 
pression was higher in the immature T  cell line, EL-4, than 
the  mature  T  cell  line,  IkMA  (Fig.  5  A,  lanes  7  and  8). 
Therefore,  Spi-B  gene  expression  increases  during  B  cell 
maturation and decreases during T  cell maturation.  Surpris- 
ingly,  some  PU.1  expression  was  also  detected  in  the 
CD4-  CD8-  sorted  T  cells  (Fig.  5  C),  although  it  was 
completely absent in a number of  human T  cell lines exam- 
ined by RT-PCR  analyses  (Jurkat,  H9, Molt 3) and puri- 
fied human peripheral  T  cells  (data not shown). RT-PCR. 
assays  for  M-CSF  receptor  expression  indicated  that  the 
RNA samples contained no contaminating monocytic cells 
(data not shown). Finally, it should be noted that Spi-B was 
found in EL-4 T  cells,  thymocytes, and the  thymus when 
these samples were run separately (Fig. 5 B). 
Spi-B Is Highly  Expressed in Human  B  Cells and Some T 
Cells at Both the RNA and Protein Levels.  Several human cell 
lines  were  examined  for  Spi-B  expression  by  poly-A  + 
RNA  Northern  blot  analysis  as  shown  in  Fig.  6.  Spi-B 
RNA w'~is detected in clone 13 B  cells  (lane  /), but was not 
present in monocytic cells  such as U937 and K562 andJur- 
kat T  cells (lanes 3-5). Furthermore, TPA treatment ofU937 
cells  (which converts them from monoblasts to monocytes) 
did  not induce  Spi-B  (lane  2).  Spi-B  expression  was  not 
apparent in the non-hematopoietic epithelial ceil line HeLa 
or Hep G2 hepatic cells  (lanes  6 and  7). 
To determine  the tissue specificity of Spi-B protein  ex- 
pression  and  to  confirm that  the  level  of gene  expression 
correlated  with  the  level  of protein  expression,  Western 
blot  analyses  were  performed.  Polyclonal antiserum  raised 
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Figure  5.  Spi-B  mRNA expression during B cell T cell development. 
(d) The top panel shows a Northern blot analysis of tkNA samples ob- 
tained from murine B and T cell lines and purified splenic B and T cells. 
B cell lines analyzed include NFS 70/c10 cells (Pro B), 38 B9 cells and 
70Z/3 cells (Pre B), and A20.1 and WEHI cells (mature t3). T cell lines 
examined include mature RMA T cells (isolated from a lymphoma) and 
immature EL-4 T cells (isolated from a thymoma). The bottom panel dis- 
plays hybridization to the control GAPDH probe. (B) RNA samples from 
A run on a separate Northern analysis to demonstrate that weak hybrid- 
ization detected in T cells was not obtained by contamination from adja- 
cent lanes exhibiting strong Spi-B expression. (C) The top panel shows 
tkT-PCtk  assays for Spi-B expression in  FACS|  CD4-  CD8- 
(DN) T cells, CD4 + CD8 + (DP) T cells, and CD4 + and CD8 + single 
positive T  cells. Also shown are RT-PCR assays performed on RNA 
samples from RAG2 -/- and C57BL/6 thymi and A20.1 mature B cells 
(positive control). The final lane shows a negative control reaction con- 
taining A20.1 B cell RNA with no reverse transcriptase (RT). The mid- 
die and bottom panels depict RT-PCR assays performed on the same 
samples for PU. 1 and mouse b-actin expression. RT-PCR products gen- 
erated for Spi-B, PU.1, and ~3-actin mRNAs were 520, 610, and 934 bp, 
respectively. 
against  human  Spi-B-GST  fusion protein  was  specific  for 
in vitro-translated  (IVT) human Spi-B in immunoblotting 
assays  (Fig. 7).  Importantly, pre-immune sera failed to bind 
IVT  Spi-B,  PU.1,  and JunB  (Fig.  7  A,  lanes  1-3),  while 
polyclonal  antisera  for Spi-B-GST  specifically recognized 
IVT  Spi-B  (lane  4).  Furthermore,  it  did  not  cross-react 
with  IVT  PU.1,  c-Fos, or JunB  (lanes  5-7).  Surprisingly, 
Exclusively in B Cells and T Cells Figure 6.  A Poly-A  + Northern blot analysis of Spi-B expression in hu- 
man cell lines. The top panel shows hybridization to a radiolabeled 3' 
UTP, probe of the human Spi-B cDNA of clone 13 B cell, U937 mono- 
blast, K562 erythroid/myeloid cells, Jurkat T cell, HepG2 hepatoma, and 
HeLa cervical carcinoma cell RNA samples. 3.7, 2.8, and 1.5-kb ILNA 
species are indicated. The bottom panel shows hybridization to the con- 
trol GAPDH radiolabeled probe. 
the antisera did not cross react with murine Spi-B (data not 
shown). The 46-kd Spi-B protein was detected in all seven 
B  cell lines examined  (Clone  13,  Raji,  CCFR-SB,  RPMI 
7666,  1LPMI 1788,  IM-9, and WIL2-NS), and one of the 
three T  cell lines (H9)  (Fig. 7, A  and B). No Spi-B protein 
was  detected  in  the  monocytic cell  lines  K562  and U937 
(Fig. 7 A, lanes 9 and  11) or HeLa epithelial cells (lane  12). 
The level  of protein  expression  correlated  with  the  abun- 
dance ofSpi-B mRNAs.  It is not surprising that Clone  13 
and  H9  express  Spi-B  proteins,  since  they  both  contain 
high levels of Spi-B rnRNAs  (Fig.  6  and data not shown). 
It is interesting to note that H9 T  cells  are less mature than 
either Jurkat  or Molt3  cells  (23).  Furthermore,  IM-9 cells 
are less mature than R.aft,  CCRF-SB, RPM1  7666, R.PM1 
1788 cells,  and WIL2-NSB cells.  Therefore,  Spi-B expres- 
sion appears  to  decrease  as  human  T  cells  mature  and in- 
crease  as  human  B  cells  mature,  as  was  noted  in  murine 
lymphocytes. Finally, no Spi-B protein was detected in pe- 
ripheral human T  cells  (data not shown). 
Spi-B  Specifically  Binds  to  Putative  PU. 1  Binding  Sites  in 
Monocytic  and B  Cell Target  Genes.  A  growing number  of 
PU. 1 target genes have been identified in monocytic and B 
cell lines, including c-fes, the M-CSF receptor, and the high 
affinity receptor for Fc fragments (Fc~/P,)  in monocytes and 
J  chain and v: and h  immunoglobulin light chains in B cells. 
To  assess  PU.1  versus  Spi-B  DNA-binding  specificity, 
electrophoretic  mobility  shift  assays  (EMSAs)  were  per- 
formed with  IVT PU.1  and Spi-B proteins.  EMSAs were 
performed so that  equal  amounts  of IVT PU. 1 and  Spi-B 
proteins  were loaded in  each reaction  to  compare the ap- 
proximate binding affinity of these two proteins to different 
PU. 1 binding sites.  Under our experimental  conditions, no 
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Figure 7.  Western  blot analysis of Spi-B protein in human cell lines. 
(A) Pre-immune sera and and-Spi-B antiserum was reacted with IVT hu- 
man Spi-B, PU.1, andJun B proteins or IVT human Spi-B, PU.1, and 
c-Fos proteins. Total cell lysates from clone 13, K562,  Jurkat, U937, and 
HeLa cells are also shown. (B) Anti-Spi-B antiserum was reacted with a 
Western blot  of lysates obtained from P,.aji, CCRF-SB,  RPMI  1666, 
R_PMI 1788, IM-9, WIL2-NS B cells, and H9 and Molt3 T cells (IVT 
human Spi-B was used as a positive control). The size of molecular mass 
standards are indicated at the left. 
proteins  other than PU. 1 and Spi-B in the TNT  reticulo- 
cyte lysate bound to the labeled oligonucleotides  (data not 
shown). The binding of both IVT PU.1  and Spi-B (which 
yielded  a  slower mobility EMSA complex)  was shown  to 
be specific in a series of competition assays  (Fig. 8 A). The 
wild-type cold competitor oligonucleotides competed with 
PU.1  and  Spi-B binding activities  (lanes  2,  5,  8,  and  11), 
but  not  competitor  oligonucleotides  harboring  mutations 
in  the  core  5'-GGAA-3' sequence  of each  PU.1  binding 
site  (lanes  3,  6,  9,  and  12).  The  binding activity of PU.1 
and Spi-B was compared for oligonucleotides derived from 
the c-fes promoter and the SV40 enhancer. The binding ac- 
tivity of Spi-B to the PU. 1-binding site in SV40 was simi- 
lar to that of PU.1, however Spi-B appeared to bind more 
weakly to the c-fes promoter (see Fig. 8 A, lanes  1, 4,  7, and 
10).  Spi-B  bound  specifically  and  with  similar  affinity  to 
PU.1  to  the  sites  in  the  M-CSFR  and  FC2tRI promoters 
(Fig.  8  B,  lanes  1-8).  However,  Spi-B  bound  to  the  PU 
sites  in J  chain promoter and the 3'  enhancer of IgK with Figure 8.  EMSAs  of Spi-B binding to published 
PU.1 binding sites in macrophage and B cell target 
genes. (A) tkadiolabeled c-fes and SV40 enhancer 
ohgonucleotides were used in gel retardation assays 
with  IVT  PU.1  and  Spi-B.  Where  indicated, a 
200-300 ng wild type (wt) or PU. 1 site  mutant (rot) 
ohgonucleotides were added to the DNA-binding 
assays. The  arrows indicate the  rapidly migrating 
PU.1/DNA complexes and slowly migrating Spi- 
B/DNA  complexes.  (B)  R.adiolabeled M-CSFP, 
promoter,  Fc"/P,.I promoter,  [3-globin intron,  J 
chain promoter,  and IgK 3'  enhancer oligonucle- 
otides were used in gel retardation assays. The ar- 
rows indicate the various PU.1/DNA and Spi-B/ 
DNA complexes. 
lower affinity than PU.1  (lanes  13-20).  Interestingly, both 
PU.1  and Spi-B bind strongly to the  ~-globin intervening 
sequence 2,  (lanes 9-12).  Table 1 summarizes the results of 
the  binding assays performed and  displays the  ohgonucle- 
otide  sequences  used.  We  observed strong  Spi-B-binding 
to  the  PU.1  sites  in  [3-globin,  M-CSFR.,  FC~/R.I  and 
weaker binding to the PU.1  sites in SV40, cofes, IgK 3', and 
J  chain. We did not find any PU. 1-binding sites that failed 
to bind IVT Spi-B. 
To determine if Spi-B in B  cell nuclear extracts can also 
bind to a PU.l-binding site in the IgK 3' enhancer, a series 
of binding  experiments  were  performed  on  extracts  ob- 
tained from clone  13  human B  cells. First, antibodies spe- 
cific for both PU.1 and Spi-B were tested for cross reactivity 
on purified proteins. As shown  in Fig. 9  A, the anti-PU.1 
antibody inhibited PU. 1 binding to a c-fes promoter oligo- 
nucleotide and did not interfere with  the binding of IVT 
Spi-B  (lanes  3  and  4).  Furthermore,  the  anti-Spi-B anti- 
210  Ets Protein Spi-B Is Expressed Exclusively in B Cells and T Cells Table 1.  Compilation of the PU. 1 and Spi-B Binding Sites 
~-globin 
M-CSF receptor 
Fo/receptor 
SV40 enhancer 
C-fes promoter 
Ig K-3' enhancer 
IgJ chain 
GATCACCTTCCTATCAGAAAAAAAGGGGAAGCGATTAT 
TCGACCTAGCTAAAAGGGGAAGAAGAGGATCAGC 
CTAGGCAATTTCCCTTCCTCTTTTCTAA 
GATCTCGGGCTCGAGTCTGAAAGAGGAACTTGGTTA 
GATCAAACCGCGGGAGGAGGAAGCGCGGAATCAGGA 
GATCCCTTTGAGGAACTGAAAACAGAACCTAGATC 
CTAGATTTTAAGAAAGCAGAAGCAGCAT 
Galson et al. 1993 
Zhang et al. 1994 
Perez et al. 1994 
Ray et al. 1992 
Heydeman et al. 1996 
Pongubala et al. 1992 
Shin et al. 1993 
body ablated Spi-B binding but did not affect PU. 1 binding 
(lanes  5 and 6). As expected, pre-immune sera did not af- 
fect the binding of either protein (lanes  7 and 8). 
Having  demonstrated that  these  antibodies  are  specific 
for either PU.1  or Spi-B, binding assays were performed 
on human B  cell nuclear extracts. As shown in Fig.  9  B, 
two specific complexes were detected using the IgK 3' oli- 
gonucleotide (bands 2 and 3 in lane  1). Both of these com- 
plexes were competed by 200 ng of cold IgK 3' oligonucle- 
otide while band 1 was not (lane 2). Pre-immune sera did 
not affect either the specific or non-specific DNA-protein 
complexes  (lane  3).  However,  the  antibody  specific  for 
Spi-B  allowed the  detection of a DNA-protein  complex 
with a rapid mobility and the antibody specific for PU.1 al- 
lowed the detection of a complex with a slower mobility 
(lanes 4 and 5). We conclude that the addition of anti-Spi-B 
antibody  allowed  the  detection  of the  rapidly  migrating 
PU.1-DNA complex and the more slowly migrating Spi-B- 
DNA  complex was  revealed by the  addition  of the  anti- 
PU.1  antibody.  When  both  Spi-B  and  PU.1  antibodies 
were added to these reactions, both PU. 1- and Spi-B-bind- 
ing were eliminated (lane  6). The migration of PU.1  and 
Spi-B was confirmed by their co-migration with IVT PU. 1 
and Spi-B  (lanes  7 and  8).  We  conclude that both PU.1 
and Spi-B in clone 13 B  cell nuclei are capable of binding 
the PU.l-binding site in the IgK 3' enhancer in an in vitro 
assay. 
Spi-B Functions as a Transcriptional Activator of a B  Cell-spe- 
cific Gene.  PU.1 and Pip (PU.1 interaction partner) form a 
B  cell-specific heterodimeric protein  complex that  regu- 
lates  the  expression of the  Igk enhancer Eh2_  4 (21).  PU.1 
and Pip bind to a composite element in this enhancer that 
is  essential for enhancer activity (20).  Furthermore, PU.1 
and Pip function as mutually dependent transcriptional ac- 
tivators  of this  element  when  coexpressed in  NIH-3T3 
cells  (21).  Having shown that Spi-B can bind to multiple 
PU.l-binding sites in B  cell--specific  genes, we wanted to 
learn if Spi-B  can also  function as  a  transactivator of the 
lambda Ex2_  4 element. The kB element ofEx2_  4 when mul- 
timerized  and  placed  upstream  of the  thymidine  kinase 
promoter, is  transactivated by PU.1  and Pip when  coex- 
pressed in NIH-3T3 cells  (21).  As shown in Fig.  10,  nei- 
ther PU.1 nor Pip transactivated the kB reporter construct 
(B4TKCAT) when expressed alone in NIH-3T3 cells. How- 
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ever,  if both PU.1  and Pip  were  cotransfected with  the 
B4TKCAT reporter DNA,  chloramphenical acetyl trans- 
ferase (CAT) activity was elevated 20-30-fold. If Spi-B and 
Pip were cotransfected with BaTKCAT, CAT expression 
was  also elevated 15-fold. Spi-B expression alone failed to 
elevate CAT activity (see Fig.  10). These results show that 
Spi-B acts as a transcriptional activator in conjunction with. 
Pip. Eisenbeis et al have shown that PU.1  is required for 
Pip to bind to the Ex2_  4 element (21).  We  conclude that 
Spi-B can also allow Pip binding and activate transcription. 
Discussion 
The Ets family of DNA-binding proteins have become 
the subject of extensive investigation as key regulators of 
immune  response  genes  and  cell  division  (24).  The  Ets 
family now includes -20 members and their cellular func- 
tions and target genes are currently being analyzed. Spi-B 
and PU.1 share a 67% amino acid Ets-domain identity and 
43% overall amino acid identity (12).  It is essential  to learn 
if Spi-B and PU. 1 have similar patterns of expression to be- 
gin  to  understand  their  respective  functions  in  develop- 
ment and immune cell function. 
In contrast to previous reports that Spi-B and PU.1  are 
coexpressed in a variety ofhematopoietic cells (12, 25), our 
data clearly showed that Spi-B expression is restricted to T 
and B  lymphocytes. We detected no human Spi-B R.NA 
or protein by poly-A  + Northern and Western blot analysis 
in monocytic or erythroid cells. We attribute the divergent 
results to the different probes used. The 3'-UTIL of Spi-B 
was used in all of our Northern blot assays as opposed to 
the full-length cDNA used in the study by Ray et al.  (12). 
Because the nucleotide sequence similarity between Spi-B 
and PU. 1 human cDNAs in the DNA-binding domain is 
75% (12), we conclude that the myeloid cell expression ob- 
served in the previous report represents cross reaction with 
PU.1.  Contrary to previous reports (12),  we also detected 
Spi-B expression in some human T  cell lines at the level of 
both RNA  and protein.  The polyclonal antiserum  raised 
against  a  human  Spi-B-GST  fusion  protein  was  able  to 
Western blot, immunoprecipitate, and ablate DNA binding 
activity of human Spi-B specifically without any cross-reac- 
tivity with PU.1.  In Western blot analysis,  Spi-B protein 
was detected in all B cell lines and one T  cell line, but not Figure 9.  Binding of PU.1 and Spi-B from clone 13 B cell nuclear extracts to the 3' enhancer oflgK. (A) A radiolabeled  c-fes promoter oligonucleotide 
was used in EMSAs with IVT PU.1 and Spi-B.  Where indicated,  pre-immune serum (P/) or antisera specific for PU.1  or Spi-B were added to DNA- 
binding reactions.  (B) A radiolabeled  oligonucleotide from the IgK 3' enhancer was used in EMSAs with nuclear extracts obtained from clone 13 B cells. 
Three DNA/protein complexes were detected and are numbered 1, 2, and 3.  Where indicated pre-immune (P/) or anti-PU.1 and anti-Spi-B antisera 
were added to DNA-binding assays. 200 ng of unlabeled competitor oligonucleotide was added to the binding reaction shown in lane 2. The mobility of 
PU. 1/DNA and Spi-B/DNA complexes  are indicated at the left. 
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in any other lineages.  Spi-B protein levels in B and T  cells 
corresponded  to  I<NA  levels;  only those  cells  with high 
Spi-B mR.NA expression had detectable Spi-B protein. 
Spi-B expression in both B cells and T cells appears to be 
tightly regulated during development. Pro-B  cells had the 
lowest levels of Spi-B mRNA and expression increased in 
pre-B  and mature B cells. The notion that mature B  ceils 
display  high levels of Spi-B  expression was  also  evident in 
tissue  studies.  Spleen,  lymph  nodes,  and purified splenic B 
cells  exhibited  high  levels  of Spi-B  expression.  Spi-B  ex- 
pression was highest in immature  CD4-  CD8-  T  cells and 
decreased  during maturation  to  the  CD4 +  CD8 +  stage  of 
development.  These  findings were  consistent with  human 
T  cells and murine  and human  T  cell lines.  The  medullary 
B4TKCAT  +  +  +  +  +  + 
PU.I  IPCDNA3  +  + 
Spi  -  BIPCDNA3  +  + 
PIPICMV  +  +  + 
Figure  10.  Functional analysis of the Spi-B protein. PU.1, Spi-B,  and 
Pip were cloned into a eukaryotic expression vector containing the CMV 
promoter and  enhancer.  The  reporter is  the B4TKCAT  construct de- 
scribed in (20) containing four kB sites upstream of the thymidine kinase 
promoter. The indicated DNAs were transiently  cotransfected  into NIH- 
3T3 ceils and extracts were analyzed for CAT activity 48 h later. The ac- 
tivity of B4TKCAT alone has been set at 1.0. The results reported are an 
average of four independent transfections. 
212  Ets Protein Spi-B Is Expressed Exclusively in B Cells and T  Cells staining  observed for Spi-B  in  the  murine  thymus would 
appear to be inconsistent with high levels of Spi-B RNA in 
CD4- CD8-  T  cells.  However, it is not clear that the pos- 
itive selection of developing thymocytes is restricted to the 
thymic  cortex  (26).  It  remains  a  formal  possibility  that 
CD4-  CDS-  T  cells  reside  in  the  medulla.  Alternatively, 
the  medullary  staining  observed may represent  expression 
in  antigen  presenting  cells  (B  cells  and  dendritic  cells). 
Other  than  the  thymus,  spleen,  and  lymph  nodes,  Spi-B 
was virtually undetectable in any other organ of either em- 
bryonic or adult mice by both poly-A  + Northern blot anal- 
ysis and in situ hybridization. 
The  expression  of Spi-B  is  clearly distinct  from that  of 
PU. 1. In situ hybridizations of fetal and adult mouse tissues 
with the 5' untranslated region of PU. 1 mRNA previously 
detected  PU.1  expression  in  bone  marrow,  liver,  and 
spleen of adults and the fetal liver of day 18.5 embryos (11). 
Further analysis showed that this was due to high levels of 
PU.1  in macrophages,  neutrophils,  mast cells,  B  cells,  and 
immature erythroid cells  (9,  11,  12). In contrast, Spi-B ex- 
pression in murine tissues is limited to the lymphoid organs 
(thymus,  spleen,  and lymph nodes)  and is  not detected  in 
the bone marrow or liver.  The lack of Spi-B expression in 
the fetal liver suggests that Spi-B is not present in immature 
proerythroblasts that are very abundant in the liver during 
days  12.5  to  16.5  of gestation.  Therefore,  macrophages, 
neutrophils,  and red blood cells which express  high levels 
of PU.1  completely lack  Spi-B.  Furthermore,  Spi-B  was 
detected  in  T  cells  where  no  PU.1  expression  was  ob- 
served.  Therefore,  only B  cells  and  CD4-  CD8-  T  cells 
express high levels of both PU. 1 and Spi-B. 
When  the  binding  affinities  of IVT  PU.1  and  Spi-B 
were  compared,  Spi-B  was  able  to  bind  to  all  published 
PU.l-binding  sites  albeit  with  less  affinity in  some  cases. 
Since both PU. 1 and Spi-B are present in B cells,  it is inter- 
esting that both were capable of binding to the 3' enhancer 
of IgK.  Although,  Spi-B  bound  efficiently  to  the  PU.1 
binding sites ofM-CSFR, FcyR1, and the scavenger recep- 
tor promoters (27), it is unlikely to regulate these genes as it 
is not present in monocytes or macrophages. It is intriguing 
that  Spi-B  can also transactivate  a reporter  construct con- 
taining the PU. 1 binding site in the lambda chain Ex2_  4 en- 
hancer.  It  will  be  of interest  to  learn  what  Spi-B  target 
genes exist in B  cells  and early T  cells.  We have previously 
shown that PU. 1 and Spi-B play nonredundant  roles in B 
cells and T  cells:  gene targeting ofPU. 1 leads to mice lack- 
ing B cells,  T  cells,  monocytes, and neutrophils (13). It will 
be of interest  to learn how lymphocytic development and 
function are affected in Spi-B-deficient mice. 
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